Veteran investor and operating executive focused on healthcare and technology transitions. Kristi Shields is a growth-stage investor and board director with experience in corporate development, M&A and scaling commercial teams. Background spans private equity and corporate strategy with emphasis on digital health, SaaS and services. Known for crossover deal execution, governance and exit planning, she supports capital raises, operational improvement and CEO-level advisory.
Veteran investor and operating executive focused on healthcare and technology transitions. Kristi Shields is a growth-stage investor and board director with experience in corporate development, M&A and scaling commercial teams. Background spans private equity and corporate strategy with emphasis on digital health, SaaS and services. Known for crossover deal execution, governance and exit planning, she supports capital raises, operational improvement and CEO-level advisory.
Growth-stage investor and board director concentrating on healthcare and enterprise software transitions. Deploys capital where product-market fit meets repeatable commercial motion, favoring digital health, SaaS and services. Blends strategic M&A lens with operational playbooks to de-risk scaling: prioritizes revenue efficiency, governance-led board oversight, and milestone-driven capital tranches. Holds a crossover bias toward carveouts and strategic exits, uses CEO-level advisement and commercial scaling as primary value-creation levers over a 3–7 year horizon.
Growth-stage investor and board director concentrating on healthcare and enterprise software transitions. Deploys capital where product-market fit meets repeatable commercial motion, favoring digital health, SaaS and services. Blends strategic M&A lens with operational playbooks to de-risk scaling: prioritizes revenue efficiency, governance-led board oversight, and milestone-driven capital tranches. Holds a crossover bias toward carveouts and strategic exits, uses CEO-level advisement and commercial scaling as primary value-creation levers over a 3–7 year horizon.
| Trades 1535 | Longs Won 1162/1535 75% | Profit Factor 22.05 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $697,668.7 |
| Average Win $89,959.48 | Best Trade (Jul 15) $25.48M | Sharpe Ratio -11.51 |
| Average Loss -$12,709 | Worst Trade (Jul 15) -$302,647.18 | Z-Score 5.4 (100%) |
| Commissions $0 | Avg. Trade Length 1y 3m 3w 2d | Expectancy $65,011.38 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% |
| Consecutive Losing Trades | 25,641 | 23,077 | 20,513 | 17,949 | 15,385 | 12,821 | 10,256 | 7,692 | 5,128 | 2,564 |